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Abstract
Background: A subclinical left ventricle diastolic dysfunction (LVDD) has been described in patients with chronic
obstructive pulmonary disease (COPD).
Objectives: To evaluate the prevalence of LVDD in stable severe COPD patients, to analyze its relationship with
exercise capacity and to look for its possible causes (lung hyperinflation, ventricular interdependence or inflammatory
mechanisms).
Methods: We evaluated 106 consecutive outpatients with severe COPD (FEV1 between 30–50%). Thirty-three (31%)
were excluded because of previous heart disease. A pulmonary function test, a 6-minute walking test (6MWT), a
Doppler echocardiography test, including diastolic dysfunction parameters, and an analysis of arterial blood gases,
NT-proBNP and serum inflammatory markers (CRP, leucocytes), were performed in all patients.
Results: The prevalence of LVDD in severe stable COPD patients was 90% (80% type I, n=57, and 10% type II,
n=7). A significant association between a lower E/A ratio (higher LVDD type I) and a lower exercise tolerance (6-
minute walked distance (6MWD)) was found (r=0.29, p<0.05). The fully adjusted multivariable linear regression
model demonstrated that a lower E/A ratio, a DLCO in the quartile 4th and a higher tobacco consumption were
associated with a lower 6MWD (76, 57 and 0.7 metres, respectively, p<0.05). A significant correlation between E/A
ratio and PaO2 was observed (r=0.26, p<0.05), but not with static lung hyperinflation, inflammation or right ventricle
overload parameters.
Conclusion: In stable severe COPD patients, the prevalence of LVDD is high and this condition might contribute in
their lower exercise tolerance. Hypoxemia could have a concomitant role in their pathogenesis.
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Introduction
Chronic obstructive pulmonary disease (COPD) is
associated with relevant extrapulmonary effects and
comorbidities that may influence the course of the disease [1].
Cardiovascular disorders are among the most prevalent. In
fact, COPD is considered an independent cardiovascular risk
factor [2,3] and ischemic heart disease is one of the main
causes of mortality in COPD [4]. Coexistence of both diseases
is very common and has diagnostic, therapeutic and prognostic
implications [5,6].
In COPD, the airflow obstruction is the major factor limiting
exercise tolerance, but patients with similar FEV1 often have
different degrees of dyspnea and exercise capacity, meaning
that there might be other factors involved. In a previous study
conducted in elderly COPD patients, the prevalence of
unrecognized heart failure was over 20%, and isolated diastolic
heart failure was involved in half of these cases [7]. However,
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little is known about its accurate prevalence in systematic
studies and its effect on the exercise capacity.
In severe emphysema, smaller cardiac cavities and lower left
ventricular (LV) end-diastolic volumes (measured by Magnetic
Resonance Imaging (MRI)) have been previously reported [8].
More recently, echocardiographic findings have demonstrated
a subclinical LV filling impairment, specially associated with the
lung static hyperinflation [9]. Moreover, LV volumes improved
in patients with severe emphysema who had undergone lung
volume reduction surgery [10,11]. All these evidences suggest
that hyperinflation plays a role, at least in advanced stages of
the disease. However, a relationship between LV diastolic
filling and a percentage of emphysema has also been observed
in patients with mild flow obstruction (without hyperinflation)
[12]. This means that other pathogenetic causes of impaired LV
filling should be investigated. Loss of vascular bed or
inflammatory mechanisms associated with COPD are
postulated as potential additional factors.
The aim of our study was to determine the prevalence of
LVDD as assessed by Doppler echocardiography in a cohort of
stable severe COPD patients. We also analyzed its impact on
functional capacity and its relation to lung hyperinflation, right
ventricular (RV) function or inflammatory parameters.
Methods
Subjects and Study Design
A cross-sectional study of a prospective cohort of
consecutive patients with stable severe COPD, who were
evaluated between March 2010 and May 2011 at the
Pulmonary Department of Bellvitge University Hospital
(Hospitalet de Llobregat, Barcelona, Spain), was performed.
Severe COPD was defined as forced expiratory volume in one
second (FEV1) between 30–50% of reference value, with a
ratio of FEV1 to FVC (forced vital capacity) below 0.70,
according to the established criteria of the Global Initiative for
Chronic Obstructive Lung Disease guidelines (GOLD) [13]. For
the purpose of our study, patients with a previous history of
coronary heart disease, heart valve disease, symptomatic
peripheral artery disease, atrial fibrillation or with a Charlson
score of more than 5 were excluded. A Doppler
echocardiogram, complete lung function tests, a 6-minute
walking test (6MWT) and blood samples and arterial gases
analysis were performed at stable stage. Patients were
considered to be in stable stage when they did not require
changes in their regular medication for at least six weeks.
Clinical and demographic data, specifically cardiovascular risk
factors, were collected. The study protocol was approved by
our institution’s local ethics committee (“Comité Ètic
d’Investigació Clínica de l’Hospital Universitari de Bellvitge”,
number PR258/09) and written informed consent was obtained
from every subject.
Blood Samples
Routine tests were done for blood count, inflammatory
markers (leukocytes and C-reactive protein (CRP)), N-terminal
pro-B-type natriuretic peptide (NT-proBNP) and analysis of
arterial blood gases.
Pulmonary Function
Pre- and post-bronchodilator spirometry (performed 15 min
after administration of 400 µg of inhaled salbutamol), static lung
volumes by plethysmography and single-breath carbon
monoxide diffusing capacity (DLCO) were measured according
to ATS/ERS recommendations using established reference
values [14].
Cardiac Function
Transthoracic echocardiographic studies were performed
using a standard device (Vivid 7, General Electrics, USA).
Measurements were done at least twice by the same operator
and were performed at rest and at end-expiration. Due to the
inherent difficulty of obtaining a good image quality of these
patients, two experienced sonographers reported the studies.
All records were considered technically acceptable to measure
diastolic dysfunction parameters.
Images comprising 2-dimensional views from parasternal
long-axis, mid-ventricular short-axis, and two and four
chambers views were collected. LV wall thickness, LV end-
diastolic and end-systolic diameters, RV diameter and left and
right atrium areas were measured according to current
recommendations. Measurement of left ventricular ejection
fraction (LVEF) was performed by M-mode echocardiography
using the Teicholtz method, by quantitative 2-D (biplane
Simpson) method, and by 2-D visually estimated method.
Parameters obtained from Doppler analysis were: peak flow
velocity of early diastolic filling (E wave), peak flow velocity of
late atrial filling (A wave) (both with and without Valsalva
maneuver), pulse-wave Doppler of pulmonary venous flow
when available and septal and lateral annular tissue Doppler
velocities (septal and lateral e’). Estimation of the systolic
pulmonary artery pressure (sPAP) was done using the modified
Bernoulli equation with an estimated right atrial pressure of 10
mmHg. Tricuspid annular plane systolic excursion (TAPSE)
was collected as variable related to RV function.
LV diastolic function was assessed by the following
variables: deceleration time of the early transmitral flow (DT),
ratio of early (E) to late (A) transmitral filling velocities (E/A
ratio) and changes with the Valsalva maneuver. It was
classified as normal or diastolic dysfunction (DD) type I
(impaired relaxation), type II (pseudonormal filling) or type III
(restrictive filling), as previously described [15]. These
guidelines were specifically used because all patients had a
normal left atrial (LA) diameter. To better evaluate LV diastolic
function and LV filling pressures, additional parameters
obtained from tissue Doppler analysis, such as septal and
lateral e´ and LV filling index (E/e’ ratio) were also considered.
Diastolic function classification was a consensus of both
sonographers.
Functional Exercise Capacity
The 6MWT was conducted according to current guidelines
[16]. Supplemental oxygen was used when patient had prior
chronic respiratory failure with domiciliary therapy.
Left Ventricle Diastolic Dysfunction in COPD
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Statistical Analysis
Data were expressed as mean ± SD or as median and
interquartile range according to whether the variable followed a
normal distribution (Kolmogorov-Smirnov test). Student t test or
Mann–Whitney U test were used for comparisons of variables
between groups, when appropriate. Categorical variables were
expressed as frequencies and percentages. Correlations
between variables were analyzed with Pearson’s coefficient. A
p value of <0.05 was considered to be statistically significant.
Association between exercise tolerance (6MWD) and LVDD
parameters (E/A ratio) were analyzed using multivariate linear
regression models adjusted for potential covariates which can
affect the exercise capacity, such as age, smoking history
(pack years), PaO2, FEV1 or inspiratory-to-total lung capacity
ratio (IC/TLC ratio). Data analysis was performed with the
statistical SSPS software (version 18.0, Chicago, IL, USA).
Results
Overall Characteristics of the Patients
A total of 106 outpatients with stable severe COPD were
evaluated during the study. Thirty-three patients (31%) were
excluded because of previous heart disease. Two additional
patients were also excluded because they presented unknown
moderate LV systolic dysfunction, defined as LVEF < 45%
[Figure 1].
The mean age of included patients was 65±7 years, and
91% (n=65) were male. All of them had been heavy smokers
and 10% (n=7) continued to smoke. They had an elevated
prevalence of cardiovascular risk factors. Table 1 shows the
clinical characteristics of the study population.
All patients were continuously treated with inhaled
corticosteroids, long-acting beta-agonists and anticholinergics,
and short-acting beta-agonists if needed. Twenty-two percent
of patients (n=16) received an angiotensin-converting enzyme
inhibitor and 8% (n=6) an angiotensin receptor antagonist.
None of them received beta-blockers.
Lung functional and analytical characteristics are given in
table 2. All these patients presented severe air trapping and
static lung hyperinflation. The average 6MWD was 372±86 m
and there was a wide range of BODE index (from 1 to 7). They
had a mean PaO2 of 68±9 mmHg. However, 21% (n=15) of
patients presented chronic respiratory failure and required
long-term oxygen therapy. Mean analytical measures of NT-
proBNP, CRP and other inflammatory markers were within the
normal range.
Cardiac Function
Table 3 shows the echocardiographic parameters. The LV
wall thickness, systolic and diastolic diameters, the filling
volume and the stroke volume tend to be low and the LA
diameter was normal in the global study population. Although
sPAP and maximal tricuspid regurgitation speed (Vmax.) average
were in the normal range, 22% (n=16) of the patients presented
echocardiographic criteria of pulmonary hypertension (PH)
(sPAP> 40 mmHg and Vmax. T> 2.8 m/s). Following classical
criteria, the overall prevalence of LVDD was 90% (n=64) (80%
type I and 10% type II). Only 7 patients (10%) presented
normal DD echocardiographic parameters, so differences in
clinical, functional and analytical characteristics between non
LVDD and LVDD groups were not considered relevant in the
analysis (Tables 2 and 3).
The prevalence of LVDD between systemic hypertension
and non-systemic hypertension patients was similar. Moreover,
no significant differences were found in the degree of DD,
measured as E/A ratio, between two groups [Figure 2, A].
Finally, although patients over 65 years had a significantly
lower E/A ratio, younger patients also had a mean E/A ratio in
the range of DD [Figure 2, B].
Exercise Tolerance
A decreased walking distance in the 6MWT was associated
with a lower E/A ratio (r=0.29, p <0.05) and a lower septal e´
(r=0.30, p<0.05) [Figure 3], both indicating a higher LVDD.
Additionally, in the univariate analysis, the lower 6MWD was
associated with lower DLCO (quartile 4th) and greater tobacco
Figure 1.  Patients evaluated during the study.  
doi: 10.1371/journal.pone.0068034.g001
Table 1. Patient characteristics.
Variables All patients (n=71)Non LVDD (n=7)LVDD (n=64)
Age, years 65.5 ± 7.5 52.9 ± 9.3 66.9 ± 5.8*
Males, n (%) 65 (91.5) 5 (71.4) 60 (93.8)
BMI, Kg/m2 27.6 ± 5.1 24.0 ± 5.3 27.9 ± 5.0
Pack-years of smoking, n 57.8 ± 24.7 48.6 ± 22.1 58.8 ± 24.9
Current smokers, n (%) 7 (9.9) 2 (28.6) 5 (7.8)
Diabetes mellitus, n (%) 13 (18.3)  13 (20.3)
Dyslipidemia, n (%) 17 (23.9)  17 (23.9)
Systemic hypertension, n (%) 29 (40.8) 2 (28.6) 27 (42.2)
Use of statins, n (%) 13 (18.3)  13 (18.3)
Use of ACEIs or ARBs, n (%) 22 (31) 2 (28.6) 20 (31.3)
Definition of abbreviations: LVDD = Left ventricle diastolic dysfunction; BMI = body
mass index; ACEI = angiotensin-converting enzyme inhibitor; ARA = angiotensin
receptor antagonist. Values are expressed as mean±standard deviation or
frequencies and percentages. *p < 0,05.
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consumption [Table 4]. DLCO quartile 4th is characteristic of
more severe emphysema. In contrast, no association was
found between 6MWD and other parameters that might have
influenced the exercise tolerance in COPD, such as FEV1, the
presence of PH (sPAP) or lung hyperinflation (IC/TLC ratio).
The fully adjusted multivariable linear regression model, with
6MWD as a dependent variable, demonstrated that for every 1
point fall in the E/A ratio, the 6MWD decreased 76m (p<0.05).
In addition, a DLCO in the quartile 4th was associated with a
decrease of 57m in the 6MWD and, for each pack-year of
tobacco consumption, the distance decreased 0.78m (p<0.05)
[Table 5]. Age had no significant influence in any of the linear
regression models.
Figure 2.  Individual data of the E/A ratio as measurement
of the left ventricle diastolic dysfunction (LVDD).  No
significant differences were found in the E/A ratio between
systemic hypertension and non-systemic hypertension patients
(A). Although patients over 65 years had a significantly lower
E/A ratio, younger patients also had a mean E/A ratio in the
range of LVDD (B). Horizontal bars represent median values
and box areas represent interquartile ranges. E/A ratio = ratio
of early (E) to late (A) transmitral filling velocities.
doi: 10.1371/journal.pone.0068034.g002
Figure 3.  Relationship between the left ventricle diastolic
dysfunction and the exercise tolerance in severe COPD
patients.  A lower 6-minute walking distance correlated with a
lower E/A ratio (A) and a lower septal e’ (B). E/A ratio = ratio of
early (E) to late (A) transmitral filling velocities.
doi: 10.1371/journal.pone.0068034.g003
Table 2. Lung functional and analytical characteristics.
Variables All patients (n=71)Non LVDD (n=7) LVDD (n=64)
FVC, % pred 73.1 ± 14.9 85.9 ± 7.5 74.9 ± 15.1
FEV1, % pred 38.5 ± 6.1 36.9 ± 4.4 38.7 ± 6.3
TLC, % pred 127.4 ± 23.2 128.7 ± 15.2 127.2 ± 24.1
RV, % pred 216.4 ± 76.8 210.4 ± 38.7 217.1 ± 80.5
IC/TLC ratio 0.27 ± 0.07 0.30 ± 0.04 0.27 ± 0.07
DLCO/VA, % pred 63.2 ± 21.9 56.1 ± 27.2 64.1 ± 21.3
mMRC scale I–II/III, n
(%) 54 (76) / 17 (24) 6 (85.7) / 1 (14.3) 48 (75) / 16 (25)
6MWD, m 372.1 ± 86.4 413.9 ± 43.2 367.5 ± 88.9
CRP, mg/L 8.3 ± 9.4 1.5 ± 0.8 8.9 ± 9.6*
NT-proBNP, ng/L 79.3 ± 70.4 64.3 ± 35.7 80.8 ± 72.9
PaO2, mmHg 68.4 ± 9.4 71.6 ± 12.3 68.1 ± 9.0
PaCO2, mmHg 44.1 ± 5.5 44.4 ± 5.8 43.9 ± 5.5
Definition of abbreviations: LVDD = left ventricle diastolic dysfunction; FVC =
forced vital capacity; % pred = % predicted; FEV1 = forced expiratory volume in 1
second; TLC = total lung capacity; RV = residual volume; IC/TLC = inspiratory-to-
total lung capacity ratio; DLCO/VA = lung diffusion capacity corrected for alveolar
ventilation; mMRC = modified Medical Research Council dyspnea scale; 6MWD =
6-minute walking distance; CRP = C-reactive protein; NT-proBNP = N-terminal pro-
B-type natriuretic peptide. Values are expressed as mean±standard deviation or
frequencies and percentages. *p < 0,05.
Table 3. Echocardiographic parameters.
Variables Non LVDD (n=7)LVDD Type I (n=57)LVDD Type II (n=7)
Septal thickness, mm* 9 ± 2.5 11 ± 1.8 10.4 ± 1.7
Posterior wall, mm 9.8 ± 1.4 9.9 ± 1.7 9.6 ± 1.6
LVED diameter, mm* 48.8 ± 5.2 46.1 ± 6.9 52.9 ± 3.7
LVES diameter, mm* 29.8 ± 4.3 29.3 ± 5.2 34.1 ± 3.1
LA diameter, mm 35.8 ± 3 36.6 ± 6.7 38.3 ± 6.0
LVED volume, mL* 63.1 ± 17.5 78.3 ± 24.6 96.3 ± 20.2
LVES volume, mL* 21.2 ± 9 28.8 ± 11.9 36.3 ± 9.6
LV stroke volume, mL 42 ± 9 49.5 ± 14.9 60.0 ± 12.5
LVEF, % 68.1 ± 5.3 63.6 ± 6.8 61.3 ± 4.4
sPAP, mmHg 39.2 ± 8.1 38.7 ± 12.6 36.3 ± 11.4
TAPSE, mm 21.3 ± 3.7 21.2 ± 4.1 23.1 ± 2.3
Basal E/A ratio* 1.1 ± 0.2 0.7 ± 0.2 1.2 ± 0.1
Valsalva E/A ratio* 0.8 ± 0.1 0.6 ± 0.1 0.7 ± 0.2
E/e’ ratio 7.3 ± 1.9 8.7 ± 2.9 11.5 ± 4.9
DT, ms* 207.5 ± 65.4 257.2 ± 62.8 177.6 ± 38.7
Definition of abbreviations: LVDD = left ventricle diastolic dysfunction; LVED = left
ventricular end-diastolic; LVES = left ventricular end-systolic; LA = left atrium;
LVEF = left ventricular ejection fraction; sPAP = systolic pulmonary artery
pressure; TAPSE = tricuspid annular plane systolic excursion; E = peak early mitral
flow velocity, A = peak late mitral flow velocity; e’ = velocity of mitral annulus early
diastolic motion; E/A ratio = ratio of early (E) to late (A) mitral flow peak velocities;
E/e’ ratio = left ventricular filling index; DT = deceleration time of the early mitral
flow. Values are expressed as mean±standard deviation. *p < 0.05 between non-
LVDD and LVDD (type I and type II) groups.
Left Ventricle Diastolic Dysfunction in COPD
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Parameters related to left ventricular diastolic
dysfunction
In our patients, no correlation was found between the degree
of LVDD, as measured by E/A ratio, and levels of NT-proBNP
or inflammatory blood markers (CRP, leukocytes), nor with
sPAP or lung hyperinflation parameters. Instead, we found a
significant correlation between LVDD, as measured by E/A
ratio, and a lower PaO2 (r=0.27, p<0.05). Finally, associations
with DLCO were consistent but not significant.
Discussion
The main finding of our study was the high prevalence of
LVDD (90%) in severe stable COPD patients. Although an
association between increasing severity of airflow obstruction
and decreased LV filling has already been described, to our
knowledge this is the first study to analyze the prevalence of
LVDD in a selected group of COPD patients with similar FEV1
 and static lung hyperinflation. Moreover, the impaired LV
diastolic filling and the reduced LV distensibility in these
patients was independently associated with a reduced exercise
tolerance as measured by the 6MWD.
Age and systemic hypertension are factors directly related to
LVDD in the general population. In fact, the prevalence of mild
LVDD in people older than 65 years with a normal LVEF is
21.7% and this increases to 27% in those older than 70 [17,18].
In our sample of severe COPD patients, classical
echocardiographic parameters of LVDD were also observed
regardless of age and lack of systemic hypertension.
Furthermore, we didn’t find echocardiographic parameters of
chronic systemic hypertension such as LV hypertrophy or LA
dilation.
Echocardiography is the most usual and feasible non-
invasive method to asses LV diastolic function. The E/A ratio
mainly represent a measurement of LV filling. According to
previous studies performed in COPD patients, a lower E/A ratio
means an increased atrial contribution to this filling [19]. This
occurs as well in the presence as in the absence of elevated
PAP [20]. However, LVDD in COPD patients could be the
result of decreased preload or pathological myocardial
compliance. It is unknown which are the best
echocardiographic parameters to measure LVDD. Evaluation of
LV function in COPD patients may be improved using tissue
Doppler echocardiography (TDE). One of the contributions of
our study was to introduce tissue Doppler echocardiography
(TDE) parameters, such as septal e´ and E/e´ratio, which are
estimated measurements of LV wall compliance.
Previous studies have already shown that physical activity in
patients with COPD is reduced [21] and that, in addition to the
respiratory disturbances, it could be associated with impaired
LV diastolic filling [22]. In our study, the exercise tolerance was
measured by the distance walked in the 6MWT, which is a
validated and reproducible test that shows the maximum
sustainable exercise [23]. Moreover, the 6MWT is a good
predictor of mortality in COPD [24]. For patients with severe
disease, the 6MWT shows marked differences between
individuals, so that the current multi-dimension indexes that
include this parameter, such as BODE, are better predictors
than the FEV1 which are used individually [25]. We
demonstrate a meaningful association between the degree of
LVDD, measured as E/A ratio and/or septal e’, and the
exercise capacity as assessed by 6MWD, in patients with the
same degree of COPD severity and significant hyperinflation.
These results add importance to the cardiovascular status in
the exercise capacity of severe COPD patients. Previous
echocardiographic studies which address the LVDD and RV
function in COPD and their relation with 6MWT present
limitations, because patients with mild or moderate airflow
obstruction have been selected [9,26,27]. Furthermore, some
of the studies did not exclude other cardiovascular diseases
and did not report the presence of systemic hypertension and
comorbidities [26,27]. Sims et al [28] demonstrated a
relationship between PH and a lower 6MWD in severe COPD
patients. In contrast, our patients, with the same degree of
severity, had lower exercise tolerance associated with higher
Table 4. Univariate analysis of clinical, lung functional and
echocardiographic variables according to the 6-minute
walking distance (m).
Variables Coefficient β (95% CI) p-value
E/A ratio 88.2 (20.4 to 156.0) 0.012*†
PaO2, mmHg 1.9 (-0.4 to 4.2) 0.102†
DLCO quartile 4th -63.2 (-110.1 to -16.3) 0.009*†
Smoking, pack-years -0.9 (-1.7 to -0.1) 0.024*†
Age, years -2.5 (-5.2 to 0.2) 0.071†
TAPSE, mm 5.0 (-0.2 to 10.2) 0.060†
FEV1, % pred 1.0 (-2.4 to 4.4) 0.557
IC/TLC ratio 3.7 (-336.2 to 343.6) 0.983
Diabetes -24.2 (-77.2 to 28.7) 0.364
Pulmonary hypertension 10.3 (-37.1 to 57.6) 0.666
BMI, kg/m2 -0.13 (-4.2 to 3.9) 0.948
Use of ACEIs / ARBs 10.7 (-33.7 to 55.2) 0.632
Definition of abbreviations: CI = confidence interval; E/A ratio = ratio of early (E) to
late (A) mitral flow peak velocities; DLCO = diffusing capacity for carbon monoxide;
TAPSE = tricuspid annular plane systolic excursion; FEV1 = forced expiratory
volume in 1 second IC/TLC = inspiratory-to-total lung capacity ratio; BMI = body
mass index; ACEI = angiotensin-converting enzyme inhibitor; ARA = angiotensin
receptor antagonist; * A p value <0.05 was considered to be statistically significant;
†p<0.2 was considered for the multivariate analysis.
Table 5. Multivariate analysis according to the 6-minute
walking distance (m) as dependent variable.
Independent variables Coefficient β (95% CI) p-value
(Constant: 368, 20 m)   
E/A ratio 76,16 (12,1 to 140,2) 0.012*
Smoking, pack-years -0,78 (-1,54 to -0,02) 0.043*
DLCO, quartile 4th -57,05 (-101,3 to -12,8) 0.021*
Definition of abbreviations: CI = confidence interval; E/A ratio = ratio of early (E) to
late (A) mitral flow peak velocities; DLCO = diffusing capacity for carbon monoxide.
* A p value of <0.05 was considered to be statistically significant.
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LVDD, regardless of structural and functional changes of RV,
measured by echocardiography.
Previous studies have shown that up to 31% of ICU
admissions with a diagnosis of severe acute exacerbation of
COPD might be of cardiac origin (associated with left heart
dysfunction measured by echocardiography, most of the cases
showing DD) and in these cases, the NT-proBNP is a
serological marker that helps in clinical diagnosis [29]. BNP
secretion might be secondary either to LV stress or to
hypoxemia, as well as to PH or RV stress. In our stable COPD
patients we did not find any relationship between the level of
NT-proBNP and the degree of LVDD, hypoxemia or the
presence of RV overload. So, it doesn’t seem to be a good
marker of LVDD in non-acute stages of the disease.
Several mechanisms might explain the presence of LVDD in
COPD patients. Watz et al. [9] described a significant
correlation between LVDD and static pulmonary hyperinflation
measured by the IC/TLC ratio in patients with different degrees
of severity of COPD. Vassaux et al [30] showed an association
between resting hyperinflation and lower oxygen pulse in
patients with severe COPD, suggesting that a decreased
cardiac function related to hyperinflation may contribute to
exercise limitation. In our study, most patients had an IC/TLC
ratio below 0.25. However, we found no significant correlation
between IC/TLC ratio and echocardiographic parameters of
LVDD, so hyperinflation might not be the only factor that
determines LVDD in these patients.
In a high percentage of patients with advanced COPD, PH
has already been described [31]. Abnormal patterns of LV
diastolic filling have been reported in patients with increased
RV afterload due to ventricular interdependence, either in
idiopathic PH [32] than in PH associated with COPD [20,33,34].
Only 22% of our patients had echocardiographic criteria of PH
(possibly underestimated), and we did not find any correlation
between sPAP and LVDD parameters. However, endothelial
dysfunction and vascular remodelling of pulmonary muscular
arteries have been demonstrated in the entire disease
spectrum, suggesting an impairment of pulmonary vessels
distensibility and a subclinical increase in pulmonary vascular
resistance [35,36]. These changes, together with loss of
vascular bed due to emphysema, may develop decreased LV
preload. In accordance with this hypothesis, a recent study has
shown a link between LV filling volume, measured by MRI, and
the degree of emphysema in patients with mild obstruction [12].
Interestingly, we observed a trend of association between the
degree of LVDD and DLCO, a functional marker largely related
to the degree of emphysema in COPD patients [37]. Some of
the patients in our study (n = 43) had a computed tomography
(CT) scan and, in these cases, we quantified the presence of
emphysema (attenuation index lower than 950 HU) with a
specific software. In the same way as Barr et al. [12] did in the
general population, we also found that a higher emphysema
index correlated with lower LV end-diastolic volume (R =
-0.321, p <0.05) in severe COPD patients. In contrast, LVDD
parameters did not change depending on the distribution of
pulmonary emphysema.
According to our results, the severity of hypoxemia
significantly correlates with the degree of LVDD in severe
COPD patients. At advanced stages of the disease, hypoxemia
is linked to the pathogenesis of pulmonary vascular
abnormalities. In fact, Dinh-Xuan et al. [36] showed that
hypoxemia is related to endothelial dysfunction. Moreover,
chronic hypoxic pulmonary vasoconstriction might generate
increasing pulmonary vascular resistance and a secondary
decreased LV filling. Likewise, hypoxemia might also directly
influence the cellular metabolism producing an impaired
myocardial relaxation and higher LVDD [38].
Systemic inflammatory parameters that were measured in
our patients (CRP, leucocytes) showed no association with
LVDD measurements, so the inflammatory mechanism defining
this disease [39,40] has not been demonstrated.
One of the strengths of the study was the homogeneous
group selection of severe COPD patients. We excluded those
with very severe COPD, since other limiting factors may
influence their exercise capacity, and those with mild/moderate
obstruction severity, because they often did not have any
symptoms. This narrow selection avoids the influence of the
degree of obstruction (FEV1) in the exercise tolerance.
Study limitations include the quality of echocardiography as a
method to measure LVDD. Secondly, the study was performed
at rest. Dynamic hyperinflation described in COPD during
exercise may play a role in LVDD of these patients. Finally, our
study was cross-sectional, so it is not possible to make firm
conclusions about causality.
In summary, the prevalence of LVDD in patients with severe
COPD is high, as assessed by standard echocardiographic
measurements, even in the younger patients group and
regardless of lack of systemic hypertension. These changes in
LV volume filling and distensibility involve a decrease in
exercise tolerance as measured by 6MWD. Besides static lung
hyperinflation, other factors could be implicated in this
condition. Loss of vascular bed due to emphysema, endothelial
dysfunction or systemic parameters such as PO2 or
inflammatory markers, also point to be causal mechanisms.
Our study suggests that LVDD has clinical consequences in
patients with severe COPD. However, further studies are
needed to establish the causal relationship between LVDD and
heart failure, one of the most prominent extrapulmonary
manifestations of COPD.
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